Inventor · disambiguated record
Benjamin Rengstl
Also filed as: RENGSTL BENJAMIN
0 granted patents·6 pending applications·0 citations·filing 2020–2022
Top patents by PatentIndex Score
6 records- 0159US2025025505A1Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancerBioNTech SE·Filed 2022·Application pending·0 cites
- 0251US2025339533A1Agents and methods for activation and targeting of immune effector cellsBIONTECH CELL & GENE THERAPIES GMBH·Filed 2022·Application pending·0 cites
- 0348US2023000962A1Treatment involving immune effector cells genetically modified to express antigen receptorsBIONTECH CELL & GENE THERAPIES GMBH·Filed 2020·Application pending·0 cites
- 0445US2022125836A1Treatment involving car-engineered t cells and cytokinesBIONTECH CELL & GENE THERAPIES GMBH·Filed 2020·Application pending·0 cites
- 0544US2023049655A1In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins)BIONTECH CELL & GENE THERAPIES GMBH·Filed 2020·Application pending·0 cites
- 0641US2022184119A1Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancersBIONTECH CELL & GENE THERAPIES GMBH·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Benjamin Rengstl files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →